ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 108 filers reported holding ATEA PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $31,385 | +428.5% | 9,482 | +545.0% | 0.00% | – |
| Q1 2024 | $5,939 | -93.6% | 1,470 | -95.2% | 0.00% | -100.0% |
| Q4 2023 | $92,537 | +132.0% | 30,340 | +128.2% | 0.00% | 0.0% |
| Q3 2023 | $39,894 | +85.6% | 13,298 | +131.4% | 0.00% | 0.0% |
| Q2 2023 | $21,490 | +195263.6% | 5,746 | +82.1% | 0.00% | – |
| Q1 2023 | $11 | -89.1% | 3,156 | -85.0% | 0.00% | -100.0% |
| Q4 2022 | $101 | -99.9% | 21,044 | +18.2% | 0.00% | +100.0% |
| Q3 2022 | $102,000 | -38.9% | 17,805 | -24.2% | 0.00% | -50.0% |
| Q2 2022 | $167,000 | +1755.6% | 23,502 | +1709.2% | 0.00% | – |
| Q1 2022 | $9,000 | -18.2% | 1,299 | +3.7% | 0.00% | – |
| Q4 2021 | $11,000 | -95.2% | 1,253 | -81.0% | 0.00% | -100.0% |
| Q3 2021 | $231,000 | +541.7% | 6,589 | +292.0% | 0.01% | +500.0% |
| Q2 2021 | $36,000 | -20.0% | 1,681 | +130.6% | 0.00% | 0.0% |
| Q1 2021 | $45,000 | +221.4% | 729 | +119.6% | 0.00% | – |
| Q4 2020 | $14,000 | – | 332 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BML Capital Management, LLC | 5,462,079 | $16,659,341 | 12.62% |
| TANG CAPITAL MANAGEMENT LLC | 4,076,741 | $12,434,060 | 1.15% |
| Stonepine Capital Management, LLC | 839,514 | $2,560,518 | 1.11% |
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $7,581,196 | 0.73% |
| CM Management, LLC | 270,000 | $823,500 | 0.66% |
| EcoR1 Capital, LLC | 6,995,861 | $21,337,376 | 0.55% |
| Acuitas Investments, LLC | 171,098 | $615,373 | 0.32% |
| Newtyn Management, LLC | 508,474 | $1,550,846 | 0.30% |
| Diametric Capital, LP | 161,524 | $492,648 | 0.30% |
| Auour Investments LLC | 177,000 | $670,830 | 0.26% |